Toujeo and Lantus contain the exact same insulin molecule, but they are not the same product and cannot be used interchangeably. Both deliver insulin glargine, a long-acting insulin that mimics the body’s steady background insulin release. The critical difference is concentration: Lantus contains 100 units per milliliter, while Toujeo packs 300 units into the same milliliter. That threefold concentration change affects how the insulin behaves in your body, how long it takes to start working, and how much you need.
Same Insulin, Different Concentration
Insulin glargine is a lab-modified version of human insulin designed to release slowly and steadily after injection. Lantus (approved by the FDA in 2000) was the original formulation at 100 units/mL. Toujeo came later as a 300 units/mL version of the same molecule. Both are made by Sanofi.
Because Toujeo is three times more concentrated, the same number of units requires only one-third the liquid volume. For someone injecting 60 units, Lantus delivers 0.6 mL of fluid under the skin, while Toujeo delivers just 0.2 mL. That smaller volume forms a more compact deposit under the skin, which changes how the insulin is absorbed into the bloodstream.
How They Work Differently in Your Body
When you inject either insulin, it forms a small depot beneath the skin that gradually releases insulin over time. Because Toujeo’s depot is more concentrated and compact, it dissolves more slowly, creating a flatter, more prolonged release profile. Neither insulin has a pronounced peak, which is what makes them useful as “background” insulins. But the timing differs in meaningful ways.
Lantus begins working within 3 to 4 hours of injection and lasts about 24 hours. Toujeo takes roughly 6 hours to begin lowering blood sugar and also lasts around 24 hours, though its activity extends more evenly across that window. That slower onset and steadier release is the main clinical advantage Toujeo was designed to offer.
Lower Risk of Low Blood Sugar
The smoother insulin release with Toujeo translates into fewer episodes of hypoglycemia, which is the most immediate safety concern with any insulin. A meta-analysis of clinical trials found that people with type 2 diabetes using Toujeo had significantly lower rates of both nighttime and total low blood sugar episodes compared to those on Lantus. For people with type 1 diabetes, the safety profile was comparable between the two.
Individual case data illustrates the difference vividly. One published case report tracked a 28-year-old man with diabetes who averaged 4.8 low blood sugar episodes per week on Lantus, including 1.5 severe episodes weekly. After switching to Toujeo, his total episodes dropped to 2.3 per week and severe episodes fell to 0.4 per week. That’s about 8 fewer low blood sugar events per month. While a single case isn’t definitive, this pattern aligns with what the larger trials consistently show.
Blood Sugar Control Is Equivalent
Both insulins lower A1c to similar degrees. The large EDITION trial series, which compared the two head-to-head, found no meaningful difference in blood sugar control. Toujeo’s advantage isn’t that it controls blood sugar better; it’s that it achieves the same control with less risk of dangerous dips.
Weight Differences
Weight gain is a common concern with insulin therapy. Data from the EDITION 2 trial showed that people on Toujeo gained significantly less weight than those on Lantus, a difference that held through 12 months of treatment. A real-world Swiss study of people with type 2 diabetes who switched to Toujeo found body weight remained essentially stable over a year. This is a modest but consistent advantage.
Switching From Lantus to Toujeo
Despite containing the same insulin molecule, the two products are not bioequivalent and not directly interchangeable. If you’re switching from Lantus to Toujeo, the starting dose is typically the same number of units you were already taking. However, clinical studies show that adults often end up needing 10 to 18% more Toujeo than their previous Lantus dose to achieve the same blood sugar targets. Children typically need about 8% more. This higher dose requirement is a direct result of the slower, more gradual absorption: some of the insulin is broken down before it ever reaches the bloodstream.
The dose adjustment happens gradually under medical guidance, not all at once. Expect a period of more frequent blood sugar monitoring while your dose is fine-tuned.
Practical Differences at a Glance
- Injection volume: Toujeo injects one-third the liquid for the same number of units, which some people find more comfortable.
- Onset: Lantus starts working in 3 to 4 hours; Toujeo takes about 6 hours.
- Steadiness: Toujeo provides a flatter, more even insulin level throughout the day.
- Hypoglycemia: Toujeo carries a lower risk, particularly at night, for people with type 2 diabetes.
- Dose: You’ll likely need a somewhat higher unit count with Toujeo to get the same effect.
- Storage: Both can be kept at room temperature (59°F to 86°F) for up to 28 days after opening.
- Delivery device: Both come in prefilled pens, though the specific pen designs differ.
Why Your Doctor Might Recommend One Over the Other
Lantus has been the standard long-acting insulin for over two decades and works well for millions of people. A switch to Toujeo typically comes up when someone is experiencing frequent low blood sugar episodes (especially overnight), when blood sugar levels swing unpredictably throughout the day, or when weight gain on insulin is a concern. People who need higher daily insulin doses may also prefer Toujeo simply because the smaller injection volume is easier to administer.
For someone starting long-acting insulin for the first time, either option can work. The choice often comes down to insurance coverage, cost, and individual blood sugar patterns. They are genuinely different products that happen to share the same active ingredient, similar to how regular-strength and extra-strength versions of the same medication behave differently even though the core drug is identical.